Vaccination should continue to be offered throughout the influenza season."
Trivalent inactivated vaccine (TIV) preparation (Fluzone Intradermal, Sanofi Pasteur) licensed in May 2011 and is indicated for people 18 to 64 years old and contains less antigen than intramuscular TIV preparations (9 μg vs 15 μg of each strain per dose) in a smaller volume (0.1 mL vs 0.5 mL).
This vaccine is administered in a single dose (preferably over the deltoid muscle) and comes in a prefilled microinjection syringe.
The most common adverse reactions include injection-site erythema, induration, swelling, pain, and pruritus.
With the exception of pain, these reactions occurred more frequently than with intramuscular vaccine, but generally resolved within 3 to 7 days.
Trivalent inactivated vaccine (TIV) preparation (Fluzone Intradermal, Sanofi Pasteur) licensed in May 2011 and is indicated for people 18 to 64 years old and contains less antigen than intramuscular TIV preparations (9 μg vs 15 μg of each strain per dose) in a smaller volume (0.1 mL vs 0.5 mL).
This vaccine is administered in a single dose (preferably over the deltoid muscle) and comes in a prefilled microinjection syringe.
The most common adverse reactions include injection-site erythema, induration, swelling, pain, and pruritus.
With the exception of pain, these reactions occurred more frequently than with intramuscular vaccine, but generally resolved within 3 to 7 days.
Comments
Post a Comment